These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effects of immunotherapy with anti-L3T4 monoclonal antibody on autoimmune cardiomyopathy: experiment with mice].
    Author: Yuan J, Liao YH, Wang ZH, Cheng X, Zhang JH, Dong JH, Wang M.
    Journal: Zhonghua Yi Xue Za Zhi; 2005 Dec 14; 85(47):3346-9. PubMed ID: 16409842.
    Abstract:
    OBJECTIVE: To evaluate the effects of immunotherapy with anti-L3T4 monoclonal antibody (McAb) on autoimmune cardiomyopathy. METHODS: 24 male Balb/c mice were immunized with mitochondria ADP/ATP carrier peptides so as to establish a model of autoimmune cardiomyopathy, and then randomly divided into 4 equal groups: cardiomyopathy control group, early-treated group injected with anti-L3T4 McAb on the day before immunization, the very day of immunization, and 1 day after the immunization, mid-term-treated group, administrated with anti-L3T4 McAb on the 89th, 90th and 91st days after immunization, and sham-immunization control group, injected with solution without anti-L3T4 McAb. Six months after blood samples were collected. The serum antibodies against ADP/ATP carrier were examined with ELISA, and the expression of IFN-gamma and IL-4, T cell cytokines, in T cells were detected by 3-color flow cytometry. The myocardium underwent pathological examination by using light and electron microscopes. The bulk percentages of cardiac collagen fiber were calculated with computer. RESULTS: Antibodies against ADP/ATP carrier were negative in the early-treated group and the sham-immunization control group and positive in the mid-term-treated and cardiomyopathy groups with a transient decline in the mid-term-treated group. By the end of 6 month, there were no cardiac morphological and histopathological changes like those in dilated cardiomyopathy (DCM) in the early-treated group and sham-immunization group, while they were found in the mid-term-treated and cardiomyopathy groups with severer myocardial impairments in the cardiomyopathy group. The percentage of IFN-gamma/IL-4 of the early-treated group was 6.56% +/- 0.21%/2.54% +/- 0.20%, not significantly different from that of the control group (5.87% +/- 0.19%/2.16% +/- 0.10%), however, the values of these 2 groups were significantly higher than those of the mid-term-treated group (8.91% +/- 0.33%/5.15% +/- 0.13%, both P < 0.01) and the cardiomyopathy group (7.85% +/- 1.42%/9.45% +/- 1.70%, both P < 0.01). CONCLUSION: Anti-L3T4 McAb administration is effective on protection from autoimmune cardiomyopathy induced by mitochondria ADP/ATP carrier peptides, especially being used at the initial phase of this disease.
    [Abstract] [Full Text] [Related] [New Search]